Oxaliplatin in Treating Patients With Metastatic Breast Cancer

Inclusion Criteria: * Participants must have metastatic breast cancer that can be biopsied or resected around 48 hours after dosing with one microdose of \[14C\]oxaliplatin (carbon C 14 oxaliplatin) * Prior radiation or surgery is allowed, but should be finished at least 2 weeks prior to study enrollment; if a participant has prior radiation therapy, at least one measurable lesion outside of the radiation field should be available for the evaluation of response to chemotherapy * Patients with metastatic breast cancer for which no standard therapy exists will be recruited for this study; more specifically, for patients with hormone receptor positive/human epidermal growth factor receptor 2 (Her2) negative disease, this includes previous therapy with tamoxifen or an aromatase inhibitor and one line of chemotherapy in the metastatic setting; for patients with Her2 positive disease, this includes 2 lines of Her2 directed therapy in the metastatic setting; and for patients with triple negative disease, this includes one line of chemotherapy in the metastatic setting; once we have identified the dose of \[14C\]oxaliplatin, we will only recruit triple negative breast cancer patients that progressed after one line of chemotherapy in the metastatic setting * Any number of prior therapies other than oxaliplatin is allowed * Eastern Cooperative Oncology Group (ECOG) performance status equal to or less than 2 (Karnofsky equal to or greater than 50%) * Life expectancy of at least 3 months * Absolute neutrophil count greater than or equal to 1,500/microL * Platelets greater than or equal to 100,000/microL * Total bilirubin less than 1.5 X institutional upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) less than or equal to 2.5 X ULN * Creatinine less than 1.5 X ULN * No pre-existing sensory neuropathy \> grade 1 * Women of child bearing potential must not be pregnant; a pre-study pregnancy test must be negative * Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 30 days after study participation * Men must agree to use adequate contraception (barrier method or abstinence) prior to study entry and for 30 days after study participation * Ability to understand and willing to sign a written informed consent document Exclusion Criteria: * Patients must not receive concomitant radiation with chemotherapy if they do not have any measurable lesions outside of the radiation field * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Participants who are pregnant or nursing * Participants who are allergic to platinum agent * Participants who have more than grade 1 peripheral neuropathy